Do analysts prefer MENS or ZVRA?

Zevra Therapeutics has a consensus target price of $27.14, indicating a potential upside of 134.80%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zevra Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82

Which has preferable valuation and earnings, MENS or ZVRA?

Zevra Therapeutics has higher revenue and earnings than Jyong Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Zevra Therapeutics $106.47M 6.45 $83.23M $1.99 5.81

Do analysts recommend MENS or CRMD?

CorMedix has a consensus target price of $14.86, suggesting a potential upside of 99.69%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CorMedix 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has stronger valuation & earnings, MENS or CRMD?

CorMedix has higher revenue and earnings than Jyong Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A CorMedix $311.71M 1.87 $163.05M $2.13 3.49

Do analysts rate MENS or CTNM?

Contineum Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 34.64%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Contineum Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger earnings & valuation, MENS or CTNM?

Jyong Biotech has higher earnings, but lower revenue than Contineum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Contineum Therapeutics $50M 11.32 -$59.98M -$1.73 N/A

Is MENS or CTNM more profitable?

Jyong Biotech's return on equity of 0.00% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Contineum Therapeutics N/A -24.73% -23.51%

Which has stronger earnings & valuation, RLMD or MENS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is RLMD or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -59.03% -53.97% Jyong Biotech N/A N/A N/A

Do analysts prefer MENS or TLRY?

Tilray Brands has a consensus price target of $11.00, indicating a potential upside of 140.70%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tilray Brands 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher earnings and valuation, MENS or TLRY?

Jyong Biotech has higher earnings, but lower revenue than Tilray Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Tilray Brands $915.45M 0.58 -$121.40M -$1.08 N/A

Jyong Biotech (MENS) Competitors

$2.03 +0.01 (+0.50%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.03 0.00 (0.00%)

As of 08/7/2026 04:23 PM Eastern

Compare

MENS vs. ZVRA, CRMD, CTNM, RLMD, and TLRY

Should you buy Jyong Biotech stock or one of its competitors? MarketBeat compares Jyong Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jyong Biotech include Zevra Therapeutics (ZVRA), CorMedix (CRMD), Contineum Therapeutics (CTNM), Relmada Therapeutics (RLMD), and Tilray Brands (TLRY). These companies are all part of the "pharmaceuticals" industry.

How does Jyong Biotech compare to Zevra Therapeutics?

Jyong Biotech (NASDAQ:MENS) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Jyong Biotech has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Jyong Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Zevra Therapeutics	$106.47M	6.45	$83.23M	$1.99	5.81

In the previous week, Zevra Therapeutics had 27 more articles in the media than Jyong Biotech. MarketBeat recorded 27 mentions for Zevra Therapeutics and 0 mentions for Jyong Biotech. Zevra Therapeutics' average media sentiment score of 0.60 beat Jyong Biotech's score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Jyong Biotech	Neutral
Zevra Therapeutics	Positive

Zevra Therapeutics has a consensus target price of $27.14, indicating a potential upside of 134.80%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

35.0% of Zevra Therapeutics shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics has a net margin of 42.82% compared to Jyong Biotech's net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Jyong Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Zevra Therapeutics	42.82%	54.54%	34.15%

Summary

Zevra Therapeutics beats Jyong Biotech on 12 of the 13 factors compared between the two stocks.

How does Jyong Biotech compare to CorMedix?

Jyong Biotech (NASDAQ:MENS) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

CorMedix has a net margin of 45.25% compared to Jyong Biotech's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Jyong Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
CorMedix	45.25%	45.57%	24.76%

34.2% of CorMedix shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CorMedix has higher revenue and earnings than Jyong Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
CorMedix	$311.71M	1.87	$163.05M	$2.13	3.49

Jyong Biotech has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

In the previous week, CorMedix had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for CorMedix and 0 mentions for Jyong Biotech. CorMedix's average media sentiment score of 1.61 beat Jyong Biotech's score of 0.00 indicating that CorMedix is being referred to more favorably in the news media.

Company	Overall Sentiment
Jyong Biotech	Neutral
CorMedix	Very Positive

CorMedix has a consensus target price of $14.86, suggesting a potential upside of 99.69%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

CorMedix beats Jyong Biotech on 12 of the 13 factors compared between the two stocks.

How does Jyong Biotech compare to Contineum Therapeutics?

Jyong Biotech (NASDAQ:MENS) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Jyong Biotech has higher earnings, but lower revenue than Contineum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Contineum Therapeutics	$50M	11.32	-$59.98M	-$1.73	N/A

Jyong Biotech's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Contineum Therapeutics	N/A	-24.73%	-23.51%

Contineum Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 34.64%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Jyong Biotech has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

In the previous week, Contineum Therapeutics had 4 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for Contineum Therapeutics and 0 mentions for Jyong Biotech. Contineum Therapeutics' average media sentiment score of 1.03 beat Jyong Biotech's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Jyong Biotech	Neutral
Contineum Therapeutics	Positive

Summary

Contineum Therapeutics beats Jyong Biotech on 6 of the 10 factors compared between the two stocks.

How does Jyong Biotech compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jyong Biotech's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-59.03%	-53.97%
Jyong Biotech	N/A	N/A	N/A

Relmada Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 142.91%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Relmada Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market.

In the previous week, Relmada Therapeutics had 7 more articles in the media than Jyong Biotech. MarketBeat recorded 7 mentions for Relmada Therapeutics and 0 mentions for Jyong Biotech. Relmada Therapeutics' average media sentiment score of 0.53 beat Jyong Biotech's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relmada Therapeutics	Positive
Jyong Biotech	Neutral

Summary

Relmada Therapeutics beats Jyong Biotech on 8 of the 12 factors compared between the two stocks.

How does Jyong Biotech compare to Tilray Brands?

Jyong Biotech (NASDAQ:MENS) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Jyong Biotech has higher earnings, but lower revenue than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Tilray Brands	$915.45M	0.58	-$121.40M	-$1.08	N/A

Tilray Brands has a consensus price target of $11.00, indicating a potential upside of 140.70%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Jyong Biotech has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Jyong Biotech has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Jyong Biotech's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Tilray Brands	-13.11%	-7.76%	-5.59%

9.4% of Tilray Brands shares are held by institutional investors. 0.8% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Tilray Brands had 23 more articles in the media than Jyong Biotech. MarketBeat recorded 23 mentions for Tilray Brands and 0 mentions for Jyong Biotech. Tilray Brands' average media sentiment score of 0.82 beat Jyong Biotech's score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Jyong Biotech	Neutral
Tilray Brands	Positive

Summary

Tilray Brands beats Jyong Biotech on 9 of the 14 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MENS vs. The Competition

Export

Metric	Jyong Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$153.58M	$11.74B	$6.94B	$12.87B
Dividend Yield	N/A	2.71%	2.59%	9.91%
P/E Ratio	N/A	793.41	270.28	25.20
Price / Sales	N/A	771.35	597.84	98.50
Price / Cash	N/A	73.00	71.46	49.72
Price / Book	-6.15	10.75	13.25	6.21
Net Income	-$4.67M	$2.77B	$3.45B	$342.45M
7 Day Performance	-5.58%	3.28%	4.65%	4.41%
1 Month Performance	-7.73%	-1.35%	-0.79%	-0.28%
1 Year Performance	-95.52%	191.23%	77.75%	22.60%

Jyong Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MENS Jyong Biotech	N/A	$2.03 +0.5%	N/A	-94.1%	$153.58M	N/A	N/A	31
ZVRA Zevra Therapeutics	4.346 of 5 stars	$10.34 +2.8%	$26.86 +159.7%	-4.7%	$610.71M	$106.47M	5.19	20	Trending News Earnings Report Analyst Forecast Analyst Revision
CRMD CorMedix	2.5401 of 5 stars	$7.54 -0.2%	$14.86 +97.2%	-31.2%	$591.91M	$311.71M	3.54	30	News Coverage Positive News Upcoming Earnings
CTNM Contineum Therapeutics	1.9638 of 5 stars	$15.53 -2.5%	$20.25 +30.4%	+123.5%	$580.48M	$50M	N/A	31
RLMD Relmada Therapeutics	2.0664 of 5 stars	$5.48 +3.3%	$12.00 +119.2%	+720.7%	$574.27M	N/A	N/A	10	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MENS) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jyong Biotech (MENS) Competitors

MENS vs. ZVRA, CRMD, CTNM, RLMD, and TLRY

How does Jyong Biotech compare to Zevra Therapeutics?

Summary

How does Jyong Biotech compare to CorMedix?

Summary

How does Jyong Biotech compare to Contineum Therapeutics?

Summary

How does Jyong Biotech compare to Relmada Therapeutics?

Summary

How does Jyong Biotech compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MENS vs. The Competition

Jyong Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jyong Biotech (MENS) Competitors

MENS vs. ZVRA, CRMD, CTNM, RLMD, and TLRY

How does Jyong Biotech compare to Zevra Therapeutics?

Which has more volatility & risk, MENS or ZVRA?

Which has preferable valuation and earnings, MENS or ZVRA?

Does the media refer more to MENS or ZVRA?

Do analysts prefer MENS or ZVRA?

Do insiders & institutionals have more ownership in MENS or ZVRA?

Is MENS or ZVRA more profitable?

Summary

How does Jyong Biotech compare to CorMedix?

Is MENS or CRMD more profitable?

Do institutionals and insiders hold more shares of MENS or CRMD?

Which has stronger valuation & earnings, MENS or CRMD?

Which has more risk and volatility, MENS or CRMD?

Does the media refer more to MENS or CRMD?

Do analysts recommend MENS or CRMD?

Summary

How does Jyong Biotech compare to Contineum Therapeutics?

Which has stronger earnings & valuation, MENS or CTNM?

Is MENS or CTNM more profitable?

Do analysts rate MENS or CTNM?

Which has more volatility & risk, MENS or CTNM?

Does the media prefer MENS or CTNM?

Summary

How does Jyong Biotech compare to Relmada Therapeutics?

Do institutionals and insiders have more ownership in RLMD or MENS?

Is RLMD or MENS more profitable?

Do analysts rate RLMD or MENS?

Which has stronger earnings & valuation, RLMD or MENS?

Which has more risk & volatility, RLMD or MENS?

Does the media prefer RLMD or MENS?

Summary

How does Jyong Biotech compare to Tilray Brands?

Which has higher earnings and valuation, MENS or TLRY?

Do analysts prefer MENS or TLRY?

Which has more risk & volatility, MENS or TLRY?

Is MENS or TLRY more profitable?

Do institutionals & insiders believe in MENS or TLRY?

Does the media refer more to MENS or TLRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MENS vs. The Competition

Jyong Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools